Navigation Links
The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxter's Cell-Based Pandemic, Avian Flu Vaccine
Date:6/11/2008

. "This is an immunogenic vaccine without the need for an adjuvant to boost the immune response."

About CELVAPAN

CELVAPAN is manufactured in a cell culture-based system in Bohumil, Czech Republic, at one of the largest cell culture vaccine production facilities in the world. Vero cell technology uses a well-established cell line originally derived from African green monkey kidneys in 1962. A continuous cell line has been derived from these cells so that an unlimited supply of cells is available without the requirement of generating additional cells from animals.

Baxter's candidate avian flu vaccine is derived from the H5N1 strain A/Vietnam/1203/2004. Its antigen composition and structure are identical to the actual virus circulating in nature without the need to enhance an immune response by including adjuvants, additives that may cause side effects. In this Phase I/II study, CELVAPAN induced an immune response that is similar to the body's defense against a natural virus infection. Earlier this year CELVAPAN was accepted for licensure review by the Committee for Medicinal Products for Human Use within the European Medicines Agency, making it the first cell culture-based pandemic influenza vaccine to be reviewed by the regulatory authority. The U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is also conducting a trial with Baxter's CELVAPAN in the United States.

Phase I/II Clinical Trial Results

The randomized Phase I/II study enrolled 284 subjects in Austria and Singapore (ages 18-45) and met its immunogenicity and safety endpoints. The study mainly investigated the ability of the vaccine to induce substantial levels of cross-immunity against divergent H5N1 strains.

The trial tested four different antigen concentrations ranging from 3.75 micrograms to 30 micrograms; 7.5 micrograms and 15 micrograms formulations were studied with and without adjuvant (additive).
'/>"/>

SOURCE Baxter International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
2. Vaccine Study in New England Journal of Medicine Wrong in Concluding Mercury Exposures are Harmless, States SafeMinds
3. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
4. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
5. New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
6. Berkery Noyes Represented The Thomson Corporation in the Sale of CenterWatch and New England Institutional Review Board to Jobson Medical Information
7. New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study
8. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
9. Adlyfe Study on the Detection of Misfolded Proteins Published in the Journal Transfusion
10. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
11. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... , April 16, 2015  Amgen (NASDAQ: ... first quarter financial results on Tuesday, April 21, 2015, ... announcement will be followed by a conference call with ... the call from Amgen will be Robert A. ... members of Amgen,s senior management team. Live ...
(Date:4/16/2015)... 2015 Today, Kenneth C. Frazier , chairman ... was elected chairman of the Board of the Pharmaceutical Research ... president and CEO John J. Castellani announced that ... New Officers Elected to PhRMA Board Frazier ... C. Read , chairman and CEO of Pfizer, Inc. Also ...
(Date:4/16/2015)... 16, 2015  Rosewind Corporation (OTCMKTS: RSWN) announced ... with a newly formed specialty healthcare company focused ... addressing urological disorders. The merged company, which is ... commenced operations and incorporates the pipeline assets of ... strategy is to build a late-stage and commercial ...
Breaking Medicine Technology:Amgen Announces Webcast Of 2015 First Quarter Financial Results 2Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 2Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 3Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 4Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 5Rosewind Corporation Shifts Focus to Develop Late-Stage Therapeutics for Urological and Related Conditions 2Rosewind Corporation Shifts Focus to Develop Late-Stage Therapeutics for Urological and Related Conditions 3
(Date:4/18/2015)... April 18, 2015 "I recognized the ... in healthcare facilities," said an inventor from Cincinnati, Ohio. ... system." , He developed the Slyde Door to offer ... in healthcare facilities. It provides convenient storage space for ... more stretchers available for patients. , This offers ...
(Date:4/18/2015)... 2015 Lowcostcarinsuranceprice.com has released a new ... on auto insurance prices . , Drivers ... vehicle theft may have to pay more for auto ... insurance policies can also offer protection against vehicle theft. ... compared online on a single website: http://lowcostcarinsuranceprice.com/ ...
(Date:4/18/2015)... April 18, 2015 In the past ... couple of changes. , "We had to run maintenance ... needed changes," said Jennifer Ramirez, the PR Director. "It ... to say that we are back on track after ... the process of changing phone systems which has not ...
(Date:4/18/2015)... “ ArcAngel ” was featured on NewsWatch as part of ... and coolest applications on the market for iOS, ... technology expert, conducted the app review and shared with viewers ... a turbulent world, people may find themselves in dangerous situations ... first move, but some situations can be avoided if there ...
(Date:4/17/2015)... John Evans, a Gardant affordable assisted living ... 2 p.m. to 3 p.m. on April 24. , ... in Pekin, Illinois, serves older adults of all incomes, ... maintain their independence. , Becky Baker will entertain guests ... served during the luau. , For more information, call ...
Breaking Medicine News(10 mins):Health News:High Rates Of Car Theft Can Have An Impact on Auto Insurance Prices! 2Health News:TheBeautyPlace.com Temporary Number Available 2Health News:A Personal Safety Application was Featured on NewsWatch Television 2Health News:John Evans Supportive Living Community Prepares for Party on the Patio 2
... BATESVILLE, Ind., Feb. 8 Hillenbrand,Industries, Inc. (NYSE: ... of $0.285 per share. This dividend was declared by ... payable on March 31, 2008 to,shareholders of record at ... ABOUT HILLENBRAND INDUSTRIES, INC., Hillenbrand Industries is organized ...
... sees greater activation of key brain region than found in ... a video game "widow," science might now be able to ... shows that the part of the brain associated with reward ... when both genders played a game whose object was to ...
... 3 Program of CGT-2168, MENLO PARK, ... named a distinguished international panel of medical ... charged with overseeing COGENT,the company,s global Phase ... antiplatelet product CGT-2168., (Logo: http://www.newscom.com/cgi-bin/prnh/20071112/COGENTUSLOGO ...
... happy and healthy ... control, WESTPORT, Conn., Feb. 8 Just in ... diabetes information,inspiration, and connection, has a spicy and informative ... people with diabetes.,Accessible at http://www.dlife.com/diabetes-valentines, the quiz ...
... sales of $20.4 million versus $24.1 ... million in the same quarter last year., - ... initial shipments expected during the second half of fiscal 2008., ... ("NAI") (Nasdaq: NAII ), a leading,formulator, manufacturer and marketer ...
... Stereotaxis, Inc. (Nasdaq:,STXS), announced today that Bevil ... Chief Financial Officer, will present at the Deutsche ... Carlton Hotel in Naples,Florida on Thursday, February 14, ... at the conference is by invitation only. The ...
Cached Medicine News:Health News:For Males, Video Game Rewards Are All in the Mind 2Health News:For Males, Video Game Rewards Are All in the Mind 3Health News:Cogentus Pharmaceuticals Names Scientific Steering Committee for Global Phase 3 Clinical Program 2Health News:Cogentus Pharmaceuticals Names Scientific Steering Committee for Global Phase 3 Clinical Program 3Health News:Love and Diabetes: dLife Valentine's Day Quiz Tests and Teaches Important Relationship Lessons for People With Diabetes 2Health News:Natural Alternatives International, Inc. Announces Second Quarter Results 2Health News:Natural Alternatives International, Inc. Announces Second Quarter Results 3Health News:Natural Alternatives International, Inc. Announces Second Quarter Results 4Health News:Natural Alternatives International, Inc. Announces Second Quarter Results 5
For the quantitative in vitro determination of Carbamazepine in human serum...
For the quantitative in vitro determination of Phenobarbital in human serum....
Determination of the Thrombin Time by STA Analyzers. Freeze-dried human thrombin (1.5NIH units/mL) with calcium....
Determination of Activated Partial Thromboplastin Time (APTT) by STA Analyzers. Cephalin reagent with particulate (silica) activator....
Medicine Products: